Candidemia and Death by Candida orthopsilosis and Candida metapsilosis in Neonates and Children  by Oliveira, Vanessa Kummer Perinazzo et al.
Pediatrics and Neonatology (2014) 55, 75e76Available online at www.sciencedirect.com
ScienceDirect
journal homepage: http: / /www.pediatr -neonatol .comBRIEF COMMUNICATIONCandidemia and Death by Candida
orthopsilosis and Candida metapsilosis
in Neonates and ChildrenVanessa Kummer Perinazzo Oliveira a,
Claudete Rodrigues Paula b, Arnaldo Lopes Colombo c,
Karina Bellinghausen Merseguel c, Angela Satie Nishikaku c,
De´bora Moreira a, Luciana da Silva Ruiz a,*aDepartment of Microbiology, Biomedical Science Institute, University of Sa˜o Paulo, Sa˜o Paulo, Brazil
bDepartment of Stomatology, School of Dentistry, University of Sa˜o Paulo, Sa˜o Paulo, Brazil
cDepartment of Medicine, Special Mycology Laboratory, Federal University of Sa˜o Paulo,
Sa˜o Paulo, BrazilReceived Mar 1, 2013; received in revised form Jun 3, 2013; accepted Jul 6, 20131. Introduction
Candida parapsilosis is the second most common yeast
causing candidemia in children. The variable genetic
composition of this taxon led to division of C. parapsilosis
group to three different species: C. parapsilosis, Candida
orthopsilosis, and Candida metapsilosis.1 The incidence of
infections related to C. orthopsilosis or C. metapsilosis
seems to be unusual.2
In Brazil, there are few data on the prevalence of these
two new species on candidemia episodes in pediatric pa-
tients as well as a lack of information about antifungal sus-
ceptibility profiles of C. orthopsilosis and C. metapsilosis.3
Our study is one of the few reports made in a Brazilian pe-
diatric hospital, but the first involving the death of neonates
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A total of three cases of fungemia by C. parapsilosis (3
different patients) were identified in the Brazilian pediatric
hospital, located in the State of Sa˜o Paulo, Brazil. The pa-
tients were a 16-day old neonate, a 10-month old infant,
and a 4-year old child, hospitalized for respiratory problems
(infant and child) and low birth weight (neonate).
After 3 days of hospitalization the patients presented
high fever chills, rapid breathing, and rapid heartbeat.
They were treated with antibiotics for 5 days, but the
symptoms remained. After fungemia confirmation, the pa-
tients were treated with fluconazole and amphotericin B
and eventually died despite treatment.
The three isolates were analyzed phenotypically and
presumptively identified as belonging to C. parapsilosis
group, and then they were also distinguished by sequencing
the internal transcribed spacer as C. orthopsilosis and C.
metapsilosis.1 This was performed according to White et al4
and de Hoog and Gerrits van den Ende5 Sequences were
analyzed and compared with available sequences ined by Elsevier Taiwan LLC. All rights reserved.
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nih.gov/Blast.cgi).
All the yeasts were studied confronting fluconazole and
amphotericin B using the Etest method. The minimum
inhibitory concentration (MIC) interpretation was done ac-
cording to CLSI-M27A3.6
Ethical clearance was obtained from the Ethical Com-
mittee of the University of Sa˜o Paulo. Quality control
strains were included throughout the study.
3. Results
Based on the molecular analysis, two samples were iden-
tified as C. orthopsilosis and one as C. metapsilosis.
Concerning the antifungal profile of fluconazole, ac-
cording to the document of CLSI-M27A3,6 we found two
susceptibility-dose dependent strains, C. orthopsilosis and
C. metapsilosis. One C. orthopsilosis was susceptible. All
the strains were susceptible to amphotericin B.
4. Discussion
The C. parapsilosis group is often associated with the use of
the central venous catheter and parenteral nutrition,
notably in childhood infections.3 The importance of these
species, as human pathogens, remains unknown. However,
they have been associated with bloodstream infections or
other anatomical sites. Interestingly, the incidence of C.
orthopsilosis and C. metapsilosis infections has increased
since 2004 with prevalence rates ranging from 2.3% to 9%
and from 0.9% to 6.9%, respectively, depending on the
geographical area and the clinical specimens analyzed.1
Cases of C. parapsilosis group can be found in hospitals
around the world.2,3 Although C. parapsilosis is the most
prevalent species found in pediatric patients with candi-
demia, C. metapsilosis and C. orthopsilosis may also be
isolated in this population, including neonates. In our study
C. orthopsilosis was isolated from the blood of a neonate
and from the blood of a child, whereas C. metapsilosis was
isolated from only one child.
Concerning the antifungal susceptibility profile, studies
in vitro have shown that these species are more susceptible
to the most common agents used in clinic. We found that
those two strains, C. orthopsilosis and C. metapsilosis,
were susceptibility-dose dependent to fluconazole. Previ-
ous reports have suggested that for both species the MICs of
amphotericin B and caspofungin are lower than those
shown by C. parapsilosis. However, MICs of fluconazole are
slightly higher when compared to the same species.7
Our study is the first in a Brazilian pediatric hospital
involving death of neonates and children due to candidemia
caused by these two new species. The neonates and children
died even after treatment with fluconazole and amphoter-
icin B. Therapeutic failure may be associated with the
pathogenesis of infections caused by these species and this is
little known. It was also noticed that the antifungal suscep-
tibility tests revealed, in vitro, susceptibility of the strains;however, there was a therapeutic failure in vivo. Flucona-
zole is one of the first-line antifungal agents of choice for the
treatment of candidemia in Brazilian hospitals, and this fact
may be related to the increased resistance to this drug found
in strains of C. orthopsilosis and C. metapsilosis.
Reports related to clinical infections with C. orthop-
silosis and C. metapsilosis are not easily found in the
literature, and it was not possible in this study to correlate
the clinical features of infection with a particular species.
Further studies are still needed to evaluate the clinical
relevance of the species of this complex.Conflicts of Interest
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